...
首页> 外文期刊>Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology >Expression, purification, and partial in vitro characterization of biologically active human coagulation factor VIII light chain (A3-C1-C2) in Pichia pastoris
【24h】

Expression, purification, and partial in vitro characterization of biologically active human coagulation factor VIII light chain (A3-C1-C2) in Pichia pastoris

机译:巴斯德毕赤酵母中具有生物活性的人类凝血因子VIII轻链(A3-C1-C2)的表达,纯化和部分体外表征

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Recombinant coagulation factor VIII (FVIII) expressed in mammalian expression systems is used extensively in the treatment of hemophilia A. It is reported that the heavy (A1-A2) and light chains (A3-C1-C2) of factor VIII purified from plasma regained the coagulation activity by dimerization in vitro. In this work, cDNA coding for the light chain of human coagulation factor VIII (FVIII-LC) was cloned into pPICZα-A expression vector downstream of alcohol oxidase promoter and α-mating signal sequence from Saccharomyces cerevisiae in order to express the protein with a native N-terminus. The methylotrophic yeast, Pichia pastoris X-33, was transformed with this cassette, and transformants were selected for production of human factor VIII light chain into culture media. SDS-PAGE and Western blot analysis confirmed the expression of factor VIII light chain protein. The expressed protein was purified to near homogeneity using histidine ligand affinity chromatography (2.342 mg/L). The biological activity of FVIII-LC was confirmed by analyzing the interaction between FVIII-LC and phospholipid vesicles. The data presented here indicate the possibilities of exploring cost-effective systems to express complex proteins of therapeutic value.
机译:在哺乳动物表达系统中表达的重组凝血因子VIII(FVIII)已广泛用于治疗血友病A。据报道,从血浆中纯化得到的因子VIII的重链(A1-A2)和轻链(A3-C1-C2)可以重新获得体外二聚化的凝血活性。在这项工作中,将编码人凝血因子VIII(FVIII-LC)轻链的cDNA克隆到酒精氧化酶启动子下游的pPICZα-A表达载体和来自酿酒酵母的α-交配信号序列中,以便用本地N端。用该盒转化甲基营养型酵母巴斯德毕赤酵母X-33,并选择转化体以将人VIII因子轻链产生到培养基中。 SDS-PAGE和Western blot分析证实了VIII因子轻链蛋白的表达。使用组氨酸配体亲和色谱法(2.342 mg / L)将表达的蛋白纯化至接近均一。通过分析FVIII-LC与磷脂囊泡之间的相互作用来确认FVIII-LC的生物学活性。本文提供的数据表明,探索具有成本效益的系统来表达具有治疗价值的复杂蛋白质的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号